1. Loser: Daiichi Sankyo

Company: Daiichi Sankyo
Symbol: $JP:4568
Beginning Price: 1524 yen
Ending Price: 1254 yen
Loss: 17.72%

If Daiichi Sankyo's top-level management are frustrated, you can't blame them. As 2012 began, the company dispatched a Japanese posse to oversee manufacturing at its troubled Indian subsidiary, Ranbaxy Laboratories. Then, the company announced Ranbaxy's precedent-setting consent decree with the FDA, which included a $500 million charge. That took its toll on the Indian company's bottom line--and, like Ranbaxy's other losses, caused a ripple effect at the parent company the following quarter. Meanwhile, the company's Effient blood thinner failed to best rival Plavix, now generic, in a clinical trial. An oncology partnership with ArQule ($ARQL) hit rocky ground as a lung cancer drug failed a late-stage trial. And as the yen lost ground against the dollar, currency losses helped undercut net income for the first 6 months of its fiscal year. The company's good news--including modest year-over-year sales growth and a new vaccine alliance with GlaxoSmithKline ($GSK)--was capped off by another fiasco at Ranbaxy. The Indian company had to recall its copy of Pfizer's ($PFE) cholesterol drug Lipitor, the drug that had helped redeem Ranbaxy in Daiichi's books, in late November.

For more:
Daiichi Sankyo opens first U.S. manufacturing plant
Ranbaxy CEO to ride out transformation under DOJ oversight

 

1. Loser: Daiichi Sankyo
Read more on

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.